The results suggested that the TP53-null HCC cell line (Hep3B) has higher sensitivity to multiple MEK inhibitors treatment than p53-mutant and p53-wild-type human HCC cell lines (Fig. S12). This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.